WASHINGTON — Pharmacogenetics-based warfarin dosing decreased adverse events compared with clinical-based dosing, investigators from the GIFT study reported at the American College of Cardiology ...
The gene-guided dosing strategy of warfarin generally leads to over-dose in patients at doses lower than 2 mg/kg, and only 50% of individual variability in daily stable doses can be explained. In this ...
Using genetic testing to help personalize doses of warfarin therapy given to patients undergoing elective orthopedic surgery appears to lower the risk of combined adverse events compared with ...
Daily warfarin dosing requirements clearly decrease with advancing age. To examine the relation between age and warfarin dosing, researchers analyzed data from 101 U.S. sites that were participating ...
† Excluding children with target INR above 3. ‡ Results presented as means. § Genotyping for variant alleles *2 and *3 only except in validation dataset, which also included test for *5, *6 and *11 ¶ ...
Similar number of out-of-range next INR values for patients with, without extended testing interval (HealthDay News) — For stable warfarin-treated patients, extended international normalized ratio ...
Digoxin was shown to be dangerous at high levels for atrial fibrillation (Afib) patients in a randomized trial. Meanwhile, another study suggested the benefit of genotyping for better warfarin ...
Patients have poor knowledge of warfarin, which may increase their risk of serious side effects, according to new research. Patients have poor knowledge of warfarin which may increase their risk of ...
Using genetic testing to help personalize doses of warfarin therapy given to patients undergoing elective orthopedic surgery appears to lower the risk of combined adverse events compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback